Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
PharmaEssentia
Pharma
PharmaEssentia plots expansion for blood cancer med Besremi
PharmaEssentia looks to file Besremi for a label expansion in essential thrombocythemia with the FDA by the end of 2025.
Zoey Becker
Jan 7, 2025 9:00am
PharmaEssentia nabs MorphoSys alum for CCO role
Dec 6, 2024 9:48am
PharmaEssentia shares rare blood cancer stories in video series
Sep 19, 2023 9:45am
New Besremi campaign focuses on what counts
Feb 24, 2023 8:20am
PharmaEssentia gains FDA approval for rare blood cancer drug
Nov 15, 2021 9:02am
FDA rejects rare disease drug, asks for prefilled syringe info
Mar 16, 2021 10:30am
